Literature DB >> 9639567

The tumour necrosis factor-sensitive pool of sphingomyelin is resynthesized in a distinct compartment of the plasma membrane.

N Andrieu-Abadie1, S Carpentier, R Salvayre, T Levade.   

Abstract

Sphingomyelin (SM) biosynthesis is believed to occur in the early Golgi apparatus, plasma membrane and recycling endosomes. In the present study, the localization of the SM synthesis that follows its hydrolysis upon activation of the SM signal-transduction pathway was investigated in human skin fibroblasts treated with tumour necrosis factor (TNF) alpha. After TNFalpha-induced degradation, the intracellular SM levels returned to baseline levels within 30-60 min in cells treated at 37 degrees C. Pretreatment or co-incubation of cells with bacterial sphingomyelinase or phospholipase C, decreasing the SM and phosphatidylcholine content in the external leaflet of the plasma membrane respectively, did not inhibit SM resynthesis. However, SM resynthesis was not observed when TNFalpha-treated cells were continuously exposed to exogenous sphingomyelinase, suggesting that under these particular conditions the resynthesized SM becomes accessible to the enzyme. Furthermore, whereas inhibition of vesicular traffic/endocytosis at 4 degrees C blocked exoplasmic SM resynthesis, it did not alter SM resynthesis in TNFalpha-treated fibroblasts, negating the role of endosomes and the Golgi apparatus. This was further evidenced by the finding that after SM resynthesis, TNFalpha was again able to promote SM turnover, even at 4 degrees C. In addition, when the exoplasmic leaflet SM was hydrolysed by treating fibroblasts with bacterial sphingomyelinase, resynthesis of SM occurred at 37 degrees C much more slowly than after TNFalpha treatment. These findings support strongly the conclusion that the SM, which is resynthesized after TNFalpha-induced hydrolysis, resides in the cytosolic leaflet of the plasma membrane, and that the process involved in this resynthesis displays characteristics different from those of the previously described SM synthases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9639567      PMCID: PMC1219560          DOI: 10.1042/bj3330091

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  48 in total

1.  Organization of phospholipids in human red cell membranes as detected by the action of various purified phospholipases.

Authors:  R F Zwaal; B Roelofsen; P Comfurius; L L van Deenen
Journal:  Biochim Biophys Acta       Date:  1975-09-16

2.  The formation of sphingomyelin from phosphatidylcholine in plasma membrane preparations from mouse fibroblasts.

Authors:  W D Marggraf; F A Anderer; J N Kanfer
Journal:  Biochim Biophys Acta       Date:  1981-04-23

Review 3.  Sphingomyelins in bilayers and biological membranes.

Authors:  Y Barenholz; T E Thompson
Journal:  Biochim Biophys Acta       Date:  1980-09-30

4.  Sphingolipid metabolism in cultured fibroblasts: microscopic and biochemical studies employing a fluorescent ceramide analogue.

Authors:  N G Lipsky; R E Pagano
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

5.  Isolation and characterization of plasma membranes from Friend erythroleukaemic cells. A study with sphingomyelinase C.

Authors:  A J Rawyler; B Roelofsen; J A Op den Kamp; L L Van Deenen
Journal:  Biochim Biophys Acta       Date:  1983-04-21

6.  Cellular and enzymic synthesis of sphingomyelin.

Authors:  D R Voelker; E P Kennedy
Journal:  Biochemistry       Date:  1982-05-25       Impact factor: 3.162

7.  The sphingomyelin pools in the outer and inner layer of the human erythrocyte membrane are composed of different molecular species.

Authors:  J P Boegheim; M Van Linde; J A Op den Kamp; B Roelofsen
Journal:  Biochim Biophys Acta       Date:  1983-11-23

8.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

9.  Acid sphingomyelinase is not essential for the IL-1 and tumor necrosis factor receptor signaling pathway leading to NFkB activation.

Authors:  K Kuno; K Sukegawa; Y Ishikawa; T Orii; K Matsushima
Journal:  Int Immunol       Date:  1994-08       Impact factor: 4.823

10.  Intracellular translocation of fluorescent sphingolipids in cultured fibroblasts: endogenously synthesized sphingomyelin and glucocerebroside analogues pass through the Golgi apparatus en route to the plasma membrane.

Authors:  N G Lipsky; R E Pagano
Journal:  J Cell Biol       Date:  1985-01       Impact factor: 10.539

View more
  5 in total

Review 1.  Ceramide: second messenger or modulator of membrane structure and dynamics?

Authors:  Wim J van Blitterswijk; Arnold H van der Luit; Robert Jan Veldman; Marcel Verheij; Jannie Borst
Journal:  Biochem J       Date:  2003-01-15       Impact factor: 3.857

2.  Rapid replenishment of sphingomyelin in the plasma membrane upon degradation by sphingomyelinase in NIH3T3 cells overexpressing the phosphatidylinositol transfer protein beta.

Authors:  C M Van Tiel; C Luberto; G T Snoek; Y A Hannun; K W Wirtz
Journal:  Biochem J       Date:  2000-03-01       Impact factor: 3.857

3.  Phosphatidylinositol transfer protein beta displays minimal sphingomyelin transfer activity and is not required for biosynthesis and trafficking of sphingomyelin.

Authors:  Bruno Ségui; Victoria Allen-Baume; Shamshad Cockcroft
Journal:  Biochem J       Date:  2002-08-15       Impact factor: 3.857

4.  Exercise training-induced changes in sensitivity to endothelin-1 and aortic and cerebellum lipid profile in rats.

Authors:  Eduardo Latorre; Maria Morán; M Dolores Aragonés; Ana Saborido; Inmaculada Fernández; Jerónimo Delgado; R Edgardo Catalán; Alicia Megías
Journal:  Lipids       Date:  2002-01       Impact factor: 1.880

Review 5.  Approaches for probing and evaluating mammalian sphingolipid metabolism.

Authors:  Justin M Snider; Chiara Luberto; Yusuf A Hannun
Journal:  Anal Biochem       Date:  2019-03-24       Impact factor: 3.365

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.